Selected events following insertion of the Progestasert system

Area of Science:

• Reproductive Health
• Contraception
• Gynecology

Background:

• The PROGESTASERT intrauterine progesterone contraceptive system (IPCS) is used for long-term contraception.
• Understanding the safety and side effect profile of IPCS during reinsertion is crucial for patient counseling and clinical practice.

Purpose of the Study:

• To analyze the incidence of adverse events following initial insertion and reinsertion of the PROGESTASERT IPCS after one year.
• To compare the risk of pelvic inflammatory disease (PID) in IPCS users with the general US population.

Main Methods:

• Analysis of selected event incidences after IPCS insertion and reinsertion.
• Comparison of PID incidence in IPCS users versus the general US population.

Main Results:

• Reinsertion did not disrupt established trends for PID, removals, unplanned pregnancies, or menstrual issues.
• IPCS use was not associated with an increased risk of PID compared to the general population.
• Expulsions and intermenstrual bleeding/spotting temporarily increased post-reinsertion but returned to baseline levels within two months.

Conclusions:

• Reinsertion of the PROGESTASERT IPCS is safe and does not adversely affect established health outcome trends.
• The PROGESTASERT IPCS does not elevate PID risk.
• Temporary increases in expulsions and spotting after reinsertion are manageable and transient.